{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:27:21Z","timestamp":1794245241366,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glycosylation is a critical quality attribute of certain therapeutic proteins, influencing efficacy, safety, and pharmacokinetics. This study analyzed glycan characterization data and drug substance release specifications from 209 Biologics License Applications (BLAs) approved by the U.S. Food and Drug Administration (FDA) through May 2025. Ten predominant Fc N-glycans were identified across IgG antibodies expressed by CHO, NS0, and Sp2\/0 cell lines, with six glycans common to all systems. Five low-abundance afucosylated glycans (&lt;\u200910%) were tightly controlled within drug substance release specifications for antibodies with Fc effector functions, although acceptance criteria varied across products. Glycan profiles were strongly dependent on the expression system: CHO-derived antibodies predominantly contained human-compatible glycan structures, whereas NS0 and Sp2\/0 antibodies introduced non-human epitopes. Fc fusion proteins exhibited higher branching and sialylation compared with conventional IgG antibodies. Notably, analysis of product labels revealed that Fc effector functions were described exclusively as\n                    <jats:italic>in vitro<\/jats:italic>\n                    observations or proposed mechanisms, with limited clinical validation. Overall, these findings establish a comprehensive benchmark for glycan profiles of FDA-approved therapeutic antibodies and underscore the need for harmonized control strategies and stronger correlation between\n                    <jats:italic>in vitro<\/jats:italic>\n                    Fc assays and clinical outcomes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-026-01207-0","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T23:14:14Z","timestamp":1769210054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Glycan Profiles of FDA-Approved Therapeutic Antibodies: Insights from Regulatory Submissions"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-6741","authenticated-orcid":false,"given":"Shen","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6508-4423","authenticated-orcid":false,"given":"Kayla","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8998-053X","authenticated-orcid":false,"given":"Sarah","family":"Rogstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7859-0843","authenticated-orcid":false,"given":"Baolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"1","key":"1207_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2443538","volume":"17","author":"S Crescioli","year":"2025","unstructured":"Crescioli S, Kaplon H, Wang L, Visweswaraiah J, Kapoor V, Reichert JM. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538.","journal-title":"MAbs"},{"issue":"3","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrd2804","volume":"8","author":"R Jefferis","year":"2009","unstructured":"Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226\u201334.","journal-title":"Nat Rev Drug Discov"},{"issue":"31","key":"1207_CR3","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","volume":"108","author":"C Ferrara","year":"2011","unstructured":"Ferrara C, Grau S, J\u00e4ger C, Sondermann P, Br\u00fcnker P, Waldhauer I, et al. Unique carbohydrate\u2013carbohydrate interactions are required for high affinity binding between Fc\u03b3riii and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1207_CR4","doi-asserted-by":"publisher","first-page":"1304365","DOI":"10.3389\/fimmu.2023.1304365","volume":"14","author":"T Damelang","year":"2023","unstructured":"Damelang T, Brinkhaus M, van Osch TLJ, Schuurman J, Labrijn AF, Rispens T, et al. Impact of structural modifications of IgG antibodies on effector functions. Front Immunol. 2023;14:1304365.","journal-title":"Front Immunol"},{"issue":"2","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/abt\/tbaf003","volume":"8","author":"JD Twomey","year":"2025","unstructured":"Twomey JD, George S, Zhang B. Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality. Antibody Ther. 2025;8(2):87\u201398.","journal-title":"Antibody Ther"},{"issue":"2","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/19420862.2015.1117719","volume":"8","author":"L Zhang","year":"2016","unstructured":"Zhang L, Luo S, Zhang B. Glycan analysis of therapeutic glycoproteins. MAbs. 2016;8(2):205\u201315.","journal-title":"MAbs"},{"issue":"3","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/19420862.2016.1149662","volume":"8","author":"L Zhang","year":"2016","unstructured":"Zhang L, Luo S, Zhang B. The use of lectin microarray for assessing glycosylation of therapeutic proteins. MAbs. 2016;8(3):524\u201335.","journal-title":"MAbs"},{"issue":"1","key":"1207_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2304268","volume":"16","author":"S Luo","year":"2024","unstructured":"Luo S, Zhang B. A tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies. MAbs. 2024;16(1):2304268.","journal-title":"MAbs"},{"issue":"1","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-023-03628-4","volume":"41","author":"S Luo","year":"2024","unstructured":"Luo S, Zhang B. Benchmark glycan profile of therapeutic monoclonal antibodies produced by mammalian cell expression systems. Pharm Res. 2024;41(1):29\u201337.","journal-title":"Pharm Res"},{"key":"1207_CR10","unstructured":"Kerry J. Antibody Production: A Guide to Choosing a Recombinant Expression System. https:\/\/www.rapidnovor.com\/antibody-production-guide-recombinant-expression-system\/ 2024 [Available from: https:\/\/www.rapidnovor.com\/antibody-production-guide-recombinant-expression-system\/."},{"issue":"2","key":"1207_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/19420862.2018.1527665","volume":"11","author":"S Loebrich","year":"2019","unstructured":"Loebrich S, Clark E, Ladd K, Takahashi S, Brousseau A, Kitchener S, et al. Comprehensive manipulation of glycosylation profiles across development scales. mAbs. 2019;11(2):335\u201349.","journal-title":"mAbs"},{"issue":"9","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/glycob\/cwz045","volume":"29","author":"S Neelamegham","year":"2019","unstructured":"Neelamegham S, Aoki-Kinoshita K, Bolton E, Frank M, Lisacek F, L\u00fctteke T, et al. Updates to the symbol nomenclature for glycans guidelines. Glycobiology. 2019;29(9):620\u20134.","journal-title":"Glycobiology"},{"issue":"30","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, O\u2019Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity*. J Biol Chem. 2002;277(30):26733\u201340.","journal-title":"J Biol Chem"},{"issue":"5","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity*. J Biol Chem. 2003;278(5):3466\u201373.","journal-title":"J Biol Chem"},{"issue":"2","key":"1207_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1158\/2326-6066.CIR-14-0125","volume":"3","author":"SD Liu","year":"2015","unstructured":"Liu SD, Chalouni C, Young JC, Junttila TT, Sliwkowski MX, Lowe JB. Afucosylated antibodies increase activation of Fc\u03b3RIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol Res. 2015;3(2):173\u201383.","journal-title":"Cancer Immunol Res"},{"key":"1207_CR16","doi-asserted-by":"crossref","unstructured":"Peschke B, Keller CW, Weber P, Quast I, L\u00fcnemann JD. Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity. Frontiers in Immunology. 2017; 8 - 2017","DOI":"10.3389\/fimmu.2017.00646"},{"issue":"7","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/glycob\/cwr027","volume":"21","author":"AM Goetze","year":"2011","unstructured":"Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949\u201359.","journal-title":"Glycobiology"},{"issue":"12","key":"1207_CR18","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/glycob\/cwv065","volume":"25","author":"D Reusch","year":"2015","unstructured":"Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325\u201334.","journal-title":"Glycobiology"},{"issue":"5","key":"1207_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","volume":"10","author":"NA Pereira","year":"2018","unstructured":"Pereira NA, Chan KF, Lin PC, Song Z. The, \u201cless-is-more\u201d in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs. 2018;10(5):693\u2013711.","journal-title":"MAbs"},{"issue":"5","key":"1207_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4161\/mabs.25423","volume":"5","author":"D Ayoub","year":"2013","unstructured":"Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, et al. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs. 2013;5(5):699\u2013710.","journal-title":"MAbs"},{"issue":"11","key":"1207_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose. N Engl J Med. 2008;358(11):1109\u201317.","journal-title":"N Engl J Med"},{"issue":"11","key":"1207_CR22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.tips.2021.08.004","volume":"42","author":"R Mastrangeli","year":"2021","unstructured":"Mastrangeli R, Audino MC, Palinsky W, Broly H, Bierau H. Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins. Trends Pharmacol Sci. 2021;42(11):943\u201356.","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"1207_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nbt.1651","volume":"28","author":"D Ghaderi","year":"2010","unstructured":"Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 2010;28(8):863\u20137.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ab.2007.01.023","volume":"364","author":"J Qian","year":"2007","unstructured":"Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption\/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 2007;364(1):8\u201318.","journal-title":"Anal Biochem"},{"issue":"3\u20134","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ijch.201400141","volume":"55","author":"C-H Chen","year":"2015","unstructured":"Chen C-H, Lin Y-P, Lin J-L, Li S-T, Ren C-T, Wu C-Y, et al. Rapid identification of terminal sialic acid linkage isomers by pseudo-MS3 mass spectrometry. Isr J Chem. 2015;55(3\u20134):412\u201322.","journal-title":"Isr J Chem"},{"key":"1207_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.113031","volume":"180","author":"B Cowper","year":"2020","unstructured":"Cowper B, Lav\u00e9n M, Hakkarainen B, Mulugeta E. Glycan analysis of erythropoiesis-stimulating agents. J Pharm Biomed Anal. 2020;180:113031.","journal-title":"J Pharm Biomed Anal"},{"key":"1207_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpba.2018.02.043","volume":"153","author":"B Cowper","year":"2018","unstructured":"Cowper B, Li X, Yu L, Zhou Y, Fan WH, Rao CM. Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan. J Pharm Biomed Anal. 2018;153:214\u201320.","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"1207_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111744","volume":"13","author":"BL Duivelshof","year":"2021","unstructured":"Duivelshof BL, Denorme S, Sandra K, Liu X, Beck A, Lauber MA, et al. Quantitative N-glycan profiling of therapeutic monoclonal antibodies performed by middle-up level HILIC-HRMS analysis. Pharmaceutics. 2021;13(11):1744.","journal-title":"Pharmaceutics"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01207-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:35:08Z","timestamp":1774460108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01207-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01207-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AI was used solely to improve language, grammar, and clarity; all scientific content and conclusions were generated by the\u00a0authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are those of the author and are based on analysis of glycosylation data in the regulatory submissions for therapeutic antibodies. They should not be construed as FDA\u2019s views or policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"No potential conflicts of interest were disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of Potential Conflicts of Interest"}}],"article-number":"53"}}